Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026)

Denali Therapeutics has reported Return on Capital Employed over the past 8 years, most recently at 55.43% for Q4 2025.

  • Quarterly Return on Capital Employed fell 1828.0% to 55.43% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55.43% through Dec 2025, down 1828.0% year-over-year, with the annual reading at 47.83% for FY2025, 588.0% down from the prior year.
  • Return on Capital Employed was 55.43% for Q4 2025 at Denali Therapeutics, down from 53.67% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 3.45% in Q2 2021 and troughed at 55.43% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 31.54% (2024), against an average of 27.43%.
  • Year-over-year, Return on Capital Employed skyrocketed 4336bps in 2021 and then plummeted -3653bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 28.2% in 2021, then decreased by -23bps to 34.77% in 2022, then soared by 49bps to 17.6% in 2023, then tumbled by -111bps to 37.15% in 2024, then crashed by -49bps to 55.43% in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Return on Capital Employed are 55.43% (Q4 2025), 53.67% (Q3 2025), and 47.31% (Q2 2025).